Medindia

X

Idenix Pharmaceuticals Highlights Progress in Three HCV Programs

Tuesday, January 12, 2010 General News J E 4
Advertisement
- Interim analysis of 50 mg cohort demonstrates potent HCV antiviral activity at 14 days for IDX184, a nucleotide polymerase inhibitor, in combination with PegIFN/Ribavirin

Idenix Pharmaceuticals Contact:

Teri Dahlman (617) 995-9905

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Amarin Corporation Announces First Patients Enroll...
S
Raptor Pharmaceutical Corp. Announces Publication ...